AstraZeneca PLC

Change company Symbol lookup

Select an option...

AZN AstraZeneca PLC

BPOP Popular Inc

BGS B&G Foods Inc

LEGAU Lead Edge Growth Opportunities Ltd

TGT Target Corp

GLBLU Cartesian Growth Corp

FCRD First Eagle Alternative Capital BDC Inc

RWAY Runway Growth Finance Corp

LITB LightInTheBox Holding Co Ltd

UEC Uranium Energy Corp

Go

--LYNPARZA combined with abiraterone will demonstrate clinical benefit regardless of biomarker status in metastatic castration-resistant prostate cancer AstraZeneca will present new data in liver, biliary tract and prostate cancers illustrating its...(BusinessWire)

AstraZeneca and Amgen today announced TEZSPIRE(TM) (tezepelumab-ekko) is now available for shipment to wholesalers in the US. TEZSPIRE was approved by the US Food and Drug Administration (FDA) on December 17, 2021 for the add-on maintenance...(BusinessWire)

Candidate Combines Fusion's Targeted Alpha Therapy (TAT) Technology with an AstraZeneca Bispecific Antibody Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as...(PR Newswire)

InvestorsObserver issues critical PriceWatch Alerts for TSLA, SGMS, NVAX, MRNA, and AZN. https://mma.prnewswire.com/media/1333368/InvestorsObserver_Logo.jpg Click a link below then choose between in-depth options trade idea report or a stock score...(PR Newswire)

--Only antibody authorized in the US for pre-exposure prophylaxis of COVID-19 AstraZeneca's EVUSHELD (tixagevimab co-packaged with cilgavimab), a long-acting antibody combination for the prevention of COVID-19, retains neutralization activity...(BusinessWire)

AstraZeneca's EVUSHELD (tixagevimab co-packaged with cilgavimab), a long-acting antibody combination for the prevention of COVID-19, retained neutralizing activity against the Omicron SARS-CoV-2 variant (B.1.1.529), according to new preclinical...(BusinessWire)

Samsung Biologics (207940.KS), the world's leading contract development and manufacturing organization, continues its strategic biopharmaceutical manufacturing collaboration with AstraZeneca (LSE/STO/Nasdaq: AZN). The partnership is based on an...(PR Newswire)

Updated results from the ASCEND Phase III trial showed AstraZeneca's CALQUENCE(R) (acalabrutinib) maintained a statistically significant progression-free survival (PFS) benefit at three years compared to investigator's choice of rituximab combined...(BusinessWire)

New results from the DESTINY-Breast03 Phase III trial showed that ENHERTU(R) (fam-trastuzumab deruxtecan-nxki) demonstrated a higher progression-free survival (PFS) and objective response rate (ORR) in pre-specified patient subgroups compared to...(BusinessWire)

--Extensive portfolio of nine approved and potential new medicines to be featured across subtypes and stages of disease, including data for novel combinations AstraZeneca will underscore its ambition to redefine care with new data from across its...(BusinessWire)

--Extensive portfolio of nine approved and potential new medicines to be featured across subtypes and stages of disease, including data for novel combinations AstraZeneca will underscore its ambition to redefine care with new data from across its...(BusinessWire)

Deutsche Bank today announced that the presentations from the November 16th and 17th Depositary Receipts Virtual Investor Conference ("dbVIC") are now available for on-demand viewing. The event featured presentations from international companies...(PR Newswire)

InvestorsObserver issues critical PriceWatch Alerts for MSFT, NIO, CG, AZN, and GILD. https://mma.prnewswire.com/media/1333368/InvestorsObserver_Logo.jpg Click a link below then choose between in-depth options trade idea report or a stock score...(PR Newswire)

Deutsche Bank today announced the lineup for its Depositary Receipts Virtual Investor Conference ("dbVIC") on Tuesday, November 16 and Wednesday, November 17, featuring live webcast presentations from international companies with American Depositary...(PR Newswire)

--New CALQUENCE tablet formulation will potentially expand eligible patient population with comparable efficacy and safety to current capsules --Emerging pipeline will also demonstrate promise of inducing deeper patient responses using novel...(BusinessWire)

Integral Molecular, an industry leader in developing antibodies against membrane proteins, announced today that it entered into an exclusive worldwide antibody license agreement with AstraZeneca (LSE/STO/Nasdaq: AZN) to develop therapeutics for...(PR Newswire)

--Recipient organizations from all across the country will deliver programs that take a community-based approach to improve local health outcomes AstraZeneca is proud to announce contributions to 30 nonprofit, community-based organizations...(BusinessWire)

Positive high-level results from the TOPAZ-1 Phase III trial showed IMFINZI(R) (durvalumab), in combination with standard-of-care chemotherapy, demonstrated a statistically significant and clinically meaningful overall survival (OS) benefit versus...(BusinessWire)

AstraZeneca, in partnership with Scientific American Custom Media, today announced the winners of the third annual Cancer Community Awards (or C2 Awards). A part of the AstraZeneca YOUR Cancer program, the C2 Awards celebrate diverse individuals and...(BusinessWire)